Sedia Biosciences

Sedia Biosciences is a US-based diagnostics company specializing in tools for disease surveillance and point-of-care testing, with a strong emphasis on global health access. The company has established market leadership with its HIV recency assays, which are critical for public health organizations to estimate HIV incidence and allocate resources. Beyond HIV, Sedia is developing a broader portfolio of rapid infectious disease diagnostics and innovative specimen collection devices. Its business model integrates product sales across diagnostics, devices, and genomics services, targeting both resource-rich and resource-limited settings.

Immunoassay (EIA) and rapid lateral flow platform for multiple specimen types (blood, oral fluid); HIV recency avidity technology; specimen collection/stabilization devices; genomics sequencing services.

Sedia is the acknowledged market leader in the specialized niche of HIV recency assays for public health. For its broader rapid POC aspirations, it competes with large diversified diagnostics companies (e.g., Abbott, Roche, Siemens Healthineers) and numerous smaller agile firms in the lateral flow space.